Categories: Healthcare

Single-Cell Genome Sequencing Market Growth Trajectory Through 2024-2033|F Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., DH Life Sciences LLC., Becton Dickinson And Company (BD), Agilent Technologies Inc.

The Single-Cell Genome Sequencing Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Single-Cell Genome Sequencing Market:
https://www.thebusinessresearchcompany.com/report/single-cell-genome-sequencing-global-market-report

According to The Business Research Company’s Single-Cell Genome Sequencing Global Market Report 2024, The single-cell genome sequencing market size has grown rapidly in recent years. It will grow from $2.17 billion in 2023 to $2.47 billion in 2024 at a compound annual growth rate (CAGR) of 14.3%. The growth in the historic period can be attributed to increased understanding of genetic heterogeneity, rising demand for precision medicine, increased cancer research, growth in prevalence of infectious diseases, increased healthcare spending.

The single-cell genome sequencing market size is expected to see rapid growth in the next few years. It will grow to $4.27 billion in 2028 at a compound annual growth rate (CAGR) of 14.6%. The growth in the forecast period can be attributed to increasing prevalence of autoimmune diseases, increasing neurological disorders, increasing government initiatives and funding, rise of contract research organizations (cros), increasing awareness of scrna-seq’s potential. Major trends in the forecast period include advancements in single-cell sequencing technologies, development of single-cell multi-omics technologies, collaborative initiatives to accelerate advancements, innovative solutions, key players’ partnerships.

Increasing the prevalence of cancer is expected to propel the growth of the single-cell genome sequencing market going forward. Cancer is a broad category of illnesses where aberrant cells develop and divide out of control. It results from changes in the genes that regulate cell division and control the normal functioning of cells. Cancer is a disease characterized by genetic alterations, and single-cell genome sequencing can help uncover the genetic changes that occur in individual cancer cells. For instance, in January 2023, according to the American Cancer Society, a US-based cancer-fighting organization, there were around 1.9 million new cancer cases and 609,360 cancer deaths in the US in 2022. Further, approximately 27.5 million new cancer cases and 16.3 million cancer deaths are estimated to occur by 2040. Therefore, the increasing prevalence of cancer is expected to propel the growth of the single-cell genome sequencing market.

Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=12655&type=smp

The single-cell genome sequencing market covered in this report is segmented –

1) By Type: Instruments, Reagents
2) By Technology: Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Quantitative Polymerase Chain Reaction (qPCR), Microarray, Multiple Displacement Amplification (MDA)
3) By Disease Area: Cancer, Immunology, Prenatal Diagnosis, Neurobiology, Microbiology, Other Disease Areas
4) By Application: Circulating Cells, Cell Differentiation Or Reprogramming, Genomic Variation, Subpopulation Characterization, Other Applications
5) By End User: Academic Research Laboratories, Biotechnology Biopharmaceutical Companies, Clinics, Other End Users

Technological advancements are a key trend gaining popularity in the single-cell genome sequencing market. Major companies operating in the single-cell genome sequencing market are focused on developing technologically advanced solutions to strengthen their position. For instance, in May 2023, Mission Bio Inc., a US-based single-cell multi-omics platform integrating genotype and phenotype for cancer research and biomarker development, introduced Tapestri Genome Editing Solution, a new end-to-end product for the analysis of genome editing. The novel method is anticipated to serve as a more effective analytical tool for developing next-generation gene-edited drugs by enabling single-cell insights that can change efficacy and safety.

The single-cell genome sequencing market report table of contents includes: